1	Dysregulation of the PRUNE2/PCA3 genetic axis in human prostate
2	cancer: From experimental discovery to validation in two
3	independent patient cohorts
4	
5	Richard C. Lauer, ^{1,2,*} Marc Barry, ^{3,*} Tracey L. Smith, ^{4,5} Andrew Maltez Thomas, ^{6,15,‡} Jin
6	Wu, ^{1,7} Ruofei Du, ⁸ Ji-Hyun Lee, ^{9,10} Arpit Rao, ¹¹ Andrey S. Dobroff, ^{1,12} Marco A. Arap, ^{13,14}
7	Diana N. Nunes, ¹⁵ Israel T. Silva, ¹⁶ Emmanuel Dias-Neto, ¹⁵ Isan Chen, ¹⁷
8	Dennis J. McCance, ^{1,7} Webster K. Cavenee, ¹⁸ Renata Pasqualini, ^{4,5,†} and Wadih Arap, ^{4,19,†}
9	
10	¹ University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, USA.
11	² Division of Hematology/Oncology, Department of Internal Medicine, University of New
12	Mexico School of Medicine, Albuquerque, New Mexico, USA.
13	³ Department of Pathology, University of Utah, Salt Lake City, Utah, USA.
14	⁴ Rutgers Cancer Institute of New Jersey, Newark, New Jersey, USA.
15	⁵ Division of Cancer Biology, Department of Radiation Oncology, Rutgers New Jersey Medical
16	School, Newark, New Jersey, USA.
17	⁶ Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, SP,
18	Brazil.
19	⁷ Department of Pathology, University of New Mexico, Albuquerque, New Mexico, USA.
20	⁸ Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock,
21	Arkansas, USA.
22	⁹ Department of Biostatistics, University of Florida, Gainesville, Florida, USA.

- 23 ¹⁰Division of Quantitative Sciences, University of Florida Health Cancer Center, Gainesville,
- Example 24 Florida, USA.
- 25 ¹¹Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine,
- 26 Houston, Texas, USA.
- ¹²Division of Molecular Medicine, Department of Medicine, Albuquerque, New Mexico, USA.
- 28 ¹³Division of Urology, University of São Paulo Medical School, São Paulo, Brazil.
- 29 ¹⁴Syrian-Lebanese Hospital, São Paulo, São Paulo, Brazil.
- 30 ¹⁵Laboratory of Medical Genomics, A.C. Camargo Cancer Center, São Paulo, São Paulo, Brazil.
- 31 ¹⁶Laboratory of Bioinformatics and Computational Biology, A.C. Camargo Cancer Center, São
- 32 Paulo, São Paulo, Brazil.
- 33 ¹⁷MBrace Therapeutics, San Diego, California, USA.
- ¹⁸Ludwig Institute for Cancer Research, University of California-San Diego, La Jolla, California,
- 35 USA.
- 36 ¹⁹Division of Hematology/Oncology, Department of Medicine, Rutgers New Jersey Medical
- 37 School, Newark, New Jersey, USA.
- 38

39 Authorship notes:

- 40 *RCL and MB contributed equally to this work. Author order was determined based on order of
- 41 joining the project.
- 42 [†]RP and WA jointly supervised the project.
- 43 [‡]AMT current address: Department of Cellular, Computational and Integrative Biology,
- 44 University of Trento, Trento, Italy.
- 45

- 46 Address correspondence to: Wadih Arap, Rutgers Cancer Institute of New Jersey, Newark, 205
- 47 South Orange Avenue, New Jersey 07101, USA. Phone: 973-972-0366; Email:
- 48 wadih.arap@rutgers.edu
- 49
- 50 Keywords: Long Noncoding RNA, oncogene, PCA3, prostate cancer, PRUNE2, tumor
- 51 suppressor gene
- 52

53 Abstract

54 BACKGROUND: We have previously shown that the long non-coding (lnc)RNA prostate 55 cancer associated 3 (PCA3; formerly prostate cancer antigen 3) functions as a trans-dominant 56 negative oncogene by targeting the previously unrecognized prostate cancer suppressor gene 57 *PRUNE2* (a homolog of the *Drosophila prune* gene), thereby forming a functional unit within a 58 unique allelic locus in human cells. Here we investigated the *PCA3/PRUNE2* regulatory axis 59 from early (tumorigenic) to late (biochemical recurrence) genetic events during human prostate 60 cancer progression. 61 **METHODS:** The reciprocal *PCA3* and *PRUNE2* gene expression relationship in paired prostate 62 cancer and adjacent normal prostate was analyzed in two independent retrospective cohorts of 63 clinically-annotated cases post-radical prostatectomy: a single-institution discovery cohort 64 (n=107) and a multi-institution validation cohort (n=497). We compared the tumor gene 65 expression of *PCA3* and *PRUNE2* to their corresponding expression in the normal prostate. We 66 also serially examined clinical/pathological variables including time to disease recurrence. 67 **RESULTS:** We consistently observed increased expression of *PCA3* and decreased expression 68 of *PRUNE2* in prostate cancer compared with the adjacent normal prostate across all tumor 69 grades and stages. However, there was no association between the relative gene expression levels 70 of PCA3 or PRUNE2 and time to disease recurrence, independent of tumor grades and stages. 71 **CONCLUSIONS:** We concluded that upregulation of the lncRNA *PCA3* and targeted 72 downregulation of the protein-coding *PRUNE2* gene in prostate cancer could be early (rather 73 than late) molecular events in the progression of human prostate tumorigenesis but are not 74 associated with biochemical recurrence. Further studies of PCA3/PRUNE2 dysregulation are 75 warranted.

76	FUNDING: We received support from the Human Tissue Repository and Tissue Analysis
77	Shared Resource from the Department of Pathology of the University of New Mexico School of
78	Medicine and a pilot award from the University of New Mexico Comprehensive Cancer Center.
79	RP and WA were supported by awards from the Levy-Longenbaugh Donor-Advised Fund and
80	the Prostate Cancer Foundation. EDN reports research fellowship support from the Brazilian
81	National Council for Scientific and Technological Development (CNPq), Brazil, and the
82	Associação Beneficente Alzira Denise Hertzog Silva (ABADHS), Brazil. This work has been
83	funded in part by the NCI Cancer Center Support Grants (CCSG; P30) to the University of New
84	Mexico Comprehensive Cancer Center (CA118100) and the Rutgers Cancer Institute of New
85	Jersey (CA072720).
86	

89 Introduction

90 Prostate cancer is the most common cancer and the second most common cause of cancer death 91 in men¹, and there continues to be a pressing need for new diagnostic and therapeutic approaches 92 for this disease, as well as better prognostic biomarkers to guide treatment. Long non-coding 93 RNA (lncRNA) species are increasingly recognized as having regulatory functions in 94 tumorigenesis, and nucleic acid-based therapeutics are being developed as a promising means of targeting pathogenic lncRNAs². Several lncRNAs have recently been found to associate with 95 96 prostate cancer, and the best known of these, prostate cancer associated 3 (PCA3; formerly 97 prostate cancer antigen 3) has been used clinically for many years as the most specific diagnostic biomarker for prostate cancer^{3,4}; however, its prognostic significance remains 98 99 uncertain. Strikingly, *PCA3* emerged first only in mammals, with further evolution in primates⁵, 100 and, given aspects of the sequence and genomic organization, we have hypothesized that it might have been introduced into the genome by an ancient oncogenic virus⁶. In humans, PCA3 has an 101 102 unusual genomic organization, being present in an antisense direction within an intron of the 103 protein-coding gene *PRUNE2*. Somewhat surprisingly for a molecule that is well-established as a 104 Food & Drug Administration (FDA)- and European Medical Agency (EMA)-approved 105 biomarker, relatively little was known about the biological function of *PCA3* until recently. 106 Ferreira et al. showed that PCA3 is androgen-regulated and that it promotes prostate cancer cell survival⁷. Subsequently, we have established that *PCA3* downregulates the expression of 107 108 *PRUNE2* in a rather unusual way: at the RNA level by RNA editing mediated via adenosine 109 deaminase RNA specific (ADAR)-family members⁸. We have showed that expressing ectopic 110 PCA3 or, alternatively, silencing PRUNE2 induced cell transformation and cell proliferation in 111 vitro, increased adhesion and migration of prostate cancer cells, and yielded larger tumors in

112	xenograft tumor models. The opposite biological effects were seen with PCA3 silencing or
113	ectopic <i>PRUNE2</i> expression ⁸ . Preliminary studies of human prostate cancer samples compared to
114	normal prostate showed increased PCA3 expression, decreased PRUNE2 expression, and
115	evidence for RNA editing of these genes. Based on these experimental findings, we proposed
116	that there is a functional molecular axis in human prostate cancer in which PCA3 acts as a
117	transdominant-negative oncogene to downregulate a previously unrecognized tumor suppressor
118	gene, PRUNE2 ⁸ .
119	
120	Here we propose that this molecular interplay may serve as a translational target for diagnostic
121	and/or therapeutic intervention in human prostate cancer. First, we present additional correlative
122	evidence from two retrospective post-surgical primary prostate cancer cohorts in support of our
123	experimental model of PCA3 as a dominant-negative oncogene and PRUNE2 as a tumor
124	suppressor gene, and for their co-regulation in human prostate cancer. Moreover, we examine the
125	dysregulation of the PCA3/PRUNE2 regulatory axis across tumors of different grades (patterns),
126	stages, and groups 9,10 . Finally, we assess whether tumor expression levels of <i>PCA3</i> and/or
127	PRUNE2 are prognostic of biochemical disease recurrence after surgery.
128	

130 Methods

131 Discovery patient cohort. Based on a power analysis using gene expression data from our prior 132 work⁸, for the UNMCCC single-institution discovery cohort, we searched the archives of the 133 Department of Pathology at the UNM School of Medicine for at least 100 consecutive patients 134 (final cohort size: n=107) who had a radical prostatectomy as the primary treatment for organ-135 confined prostate cancer between the years 2001 and 2013 and who had the following clinical 136 and pathological attributes: final post-prostatectomy Gleason Score 7 [either Gleason Group 2 137 (3+4) or Gleason Group 3 (4+3)], pathologic stage pT2 or pT3a, negative surgical margins, 138 negative for seminal vesicle invasion, no evidence of local or distant metastasis, and no prior 139 treatment for prostate cancer. The following additional data were retrospectively abstracted from 140 the individual medical records: age at surgery, race, presence of recurrence, type of recurrence (i.e., biochemical, local, metastatic), and disease-free survival time. Biochemical disease 141 142 recurrence was defined as a detectable serum prostate-specific antigen (PSA) concentration of at 143 least 0.2 ng/mL post-operatively. Lost to follow up was defined as not having been followed up 144 at the UNMCCC after their urological surgery. All included cases had an independent pathologic 145 re-review by a Board-certified pathologist with expertise in urological oncology (MB), with 146 confirmation of diagnosis, Gleason-based analysis (grading, scoring, and grouping), standard 147 TNM staging, and margin status post-resection. A small number of identified cases (<5%) had to 148 be excluded due to the very limited amount of tumor present.

149

150 Microdissection of tumor and normal prostate (nonneoplastic prostatic glandular tissue) for the

151 *discovery cohort.* To obtain tumor for RNA analysis, a representative carcinoma-containing

152 formalin-fixed paraffin embedded (FFPE) block was chosen from each case. Contiguous foci of

tumor were marked on the glass slide such that the density of tumor cells was at least 75%. The boundary of the corresponding areas on the tumor block was scored with a blade tip, effectively allowing microdissection of tumor in the process of microtome sectioning. Multiple $10\mu m$ sections were cut, depending on the area of the tumor focus/foci. In 24 (22.4%) of the cases, we also microdissected areas of nonneoplastic prostatic glandular tissue away from tumor in a similar manner, again also aiming for at least 75% epithelial density.

159

160 Measurement of PRUNE2 and PCA3 gene expression in the discovery cohort by quantitative RT-161 PCR. Briefly, gene expression for PCA3 and PRUNE2 were determined by quantitative reverse 162 transcription polymerase chain reaction (qRT-PCR) by using TaqMan gene expression assays 163 (Thermo Fisher Scientific) with amplicon detection via a LightCycler 96 (Roche Diagnostics). 164 Gene expression was quantified by the relative logarithmic RT-PCR threshold cycles (ΔCt) between the target genes and housekeeping control genes¹¹. Specifically, total RNA was 165 166 extracted from the microdissected FFPE sections using the PureLink[™] FFPE Total RNA 167 Isolation Kit (Thermo Fisher Scientific, Cat. No. K1560-02). RNA was quantified on a 168 NanoDrop ND-1000 Spectrophotometer (Thermo Fisher Scientific), and the average A260/A280 169 ratio was 1.94 (range 1.88 to 2.07), indicating optimal quality of the RNA extracted for gene 170 expression assays. RNA was then further quantified with the Qubit® RNA HS Assay Kit 171 (Thermo Fisher Scientific, Cat. No. Q32852) on a Qubit 2.0 (Thermo Fisher Scientific) for 172 accurate RNA concentration. RNA integrity was evaluated with the Agilent RNA 6000 Nano kit 173 (Agilent Technologies, Cat. No. 5067-1511) on an Agilent 2100 Bio analyzer (Agilent 174 Technologies). To remove genomic DNA contamination, RNA samples were treated with 2U of

175	DNase I (Thermo Fisher Scientific, Cat. No. 18068-015) per 2µg of total RNA. All procedures
176	were performed according to the manufacturer's standard protocols.
177	
178	Reverse Transcription was performed in triplicate in order to create enough cDNA for the entire
179	project. 500ng RNA in each of three tubes was reverse transcribed with the High-Capacity RNA
180	to-cDNA TM Kit (Thermo Fisher Scientific, Cat. No. 4387406) in a final volume of 20µl,

- 181 according to the manufacturer's instructions. Reverse transcription was carried out in a Gene
- 182 Amp PCR System 9700 (Applied Biosystems) at 37°C for 60 minutes and terminated by 95°C for
- 183 5 minutes. Then three aliquots were combined for the following experiments.

184

185 For the Thermo Fisher Scientific TaqMan gene expression assay experiments, three

186 (Hs00322421_m1, Hs00999960_m1, and Hs01060890_m1) and two (Hs01371939_g1 and

187 Hs03462121_m1) assays were chosen for target genes *PRUNE2* and *PCA3* respectively,

188 (designated PR1, PR2 and PR3, and PC1 and PC2). Three endogenous controls GAPDH

189 (Hs02758991_g1), HPRT1 (Hs02800695_m1), and UBC (Hs01871556_s1) were selected

190 (designated C1, C2 and C3)¹². Each *PRUNE2* assay and *PCA3* assay was labeled with FAM and

191 paired with a VIC labeled endogenous control in a duplex reaction, with separate reactions to

include all of the three endogenous controls. Therefore, a total of fifteen duplex gene expression

193 mixes, nine for *PRUNE2* and six for *PCA3*, was required for all specimens (Fig. 1 - Source Data

194 File 1 [tumor] and Fig. 1 - Source Data File 2 [normal]).

195

196 Each duplex gene expression assay was then performed in triplicate for all specimens following

197 manufacturer's standard protocols, for a total of 45 expression measures for each case. qRT-PCR

198	was performed with the TaqMan Gene Expression Master Mix (Thermo Fisher Scientific, Cat.
199	No. 4369514) using 1µl of each TaqMan target gene assay (20×FAM) and endogenous controls
200	assay (20×VIC), 1µl of cDNA template (equivalent to 25ng RNA input), and 7µl of RNase-free
201	water for a 20µl final reaction mixture. A non-template control was included in every master mix
202	in every 96-format tray. In addition, in order to evaluate inter-plate variation, we also included
203	one RNA sample, in triplicate, in all the 96 format trays. Analysis of these controls indicated that
204	there were no significant batch effects (data not shown). The qRT-PCR product detection was
205	achieved on a LightCycler 96 (Roche Diagnostics). The cycle program was: at 95°C for 10
206	minutes, followed by 40 cycles at 95°C for 15 seconds and at 60°C for 1 minute. Quantification
207	of target and control genes (Cq) in each sample was performed by LightCycler® 96 SW 1.1
208	(Roche Diagnostics).

209

210 Validation patient cohort. For the TGCA patient validation cohort (n=497 patients), we first 211 downloaded clinical data along with the expression of the lncRNA PCA3 and the PRUNE2 gene (http://cancergenome.nih.gov) with the UCSC Xena browser^{13,14}, together with paired 212 213 nonneoplastic samples in 52 of the cases (10.5%). The following clinical and pathological 214 characteristics were included in the study: age at diagnosis, vital status, tumor Gleason-based 215 analysis (grading, scoring, grouping), pathological stage, status of biochemical recurrence, and time to recurrence. Gene expression was calculated with RSEM^{15,16}. By using the available 216 217 dataset, we evaluated *PCA3* and *PRUNE2* gene expression values in terms of tumor versus 218 nonneoplastic prostate, biochemical recurrence, pathologic T stage, Gleason analysis (Grade, 219 Score, and Group), age at pathology-proven diagnosis. Because the regulation of *PRUNE2* by 220 *PCA3* occurs at the RNA level by the formation of an RNA hetero-duplex, we also evaluated the

ratio of the expression of the two genes in terms of the clinical and pathological variables foreach patient of the cohort.

223

Statistics. Demographic and clinical variables were summarized with descriptive statistics. For
the discovery cohort, the mean and median of gene expressions across multiple control genes and
assays were summarized, and these were used as measures for gene expression of *PRUNE2* and *PCA3* relative to endogenous housekeeping controls for each case. More detailed methods are
described in the supplemental materials.

230 Testing for differences of *PCA3* and *PRUNE2* expression between paired tumor and

231 nonneoplastic prostate expression was by the Wilcoxon signed rank test. The Kruskal-Wallis test 232 was used when comparing three or more groups. Assessment for significant differences of gene 233 expression by recurrence status was by Wilcoxon rank sum test. The Kaplan-Meier product limit 234 method with log-rank test was used to explore the relationship between gene expression levels or 235 the ratio and the time to recurrence. Multivariable Cox proportional hazard modeling was used to 236 fit for the association between time to recurrence and expression levels of *PRUNE2* or *PCA3* or 237 their ratio, while controlling for multiple clinical covariates. All statistical analyses were carried 238 out by using the SAS (9.4) or R software package (R 3.4.5), unless otherwise indicated (R and 239 SAS codes are available in the Source Code File).

240

241 Study approval. For the discovery cohort, there was University of New Mexico Health Sciences

242 Institutional Review Board (IRB) approval (HRRC15-138), and the study was carried out in

accordance with the United States Common Rule.

244 Results

245 Discovery Single-Institutional Cohort

246 In the initial single-institution discovery cohort from the University of New Mexico

- 247 Comprehensive Cancer Center (UNMCCC), patients with intermediate-risk (Gleason Score 7;
- corresponding to Gleason Groups 2 and 3) organ-confined prostate cancer (n=107) met the
- criteria for inclusion in this study (Table 1). Briefly, the mean age of the cohort was 63 years old
- 250 (ranging from 45 to 84 years old); most patients (85%) were non-Hispanic white, but Hispanic
- 251 (7.5%), American Indian/Native American (2.8%), and African American (2.8%) men were also
- represented. All patients had final Gleason Score 7 adenocarcinoma after radical prostatectomy,
- with 86.9% being 3+4=7 (Gleason Group 2) and 13.1% being 4+3=7 (Gleason Group 3). The

254 pathologic stage distribution was as follows: 74.8% were pT2 and 25.2% were pT3a. Nineteen of

the patients (17.8%) had biochemical recurrence discovered during follow up, including one with

documented local recurrence and one with documented metastases. Five patients (4.7%) were

lost to follow up.

258

259 RNA extraction and quantitative real-time polymerase chain reaction (qRT-PCR) were

successful in all microdissected tumor samples (n=107). In 24 of these cases (22.4%), we

261 extracted RNA from benign prostatic glandular tissue away from tumor (hereafter termed

262 "normal prostate": qRT-PCR was successful in all cases for PRUNE2 (n=24, 100%) and in most

263 cases for PCA3 (n=21, 87.5%). Comparing PRUNE2 and PCA3 expression in prostatic

adenocarcinoma with expression in normal prostate (all relative to endogenous housekeeping

controls), we found consistent trends for both genes in multiple assays, with lower expression of

266 *PRUNE2* in tumor as compared with normal prostate and higher expression of *PCA3* in tumor as

267	compared with normal prostate (Fig. 1 - Source Data File 3). These results are summarized in
268	Figure 1A and as follows. Relative to controls, PCA3 expression was significantly higher in
269	prostatic adenocarcinoma (mean: 2.46; standard deviation: 1.28) than normal prostate (-1.99;
270	2.63, [p-value<0.001]). Relative to controls, PRUNE2 expression was significantly lower in
271	tumor (mean: -1.48; standard deviation: 0.92) than normal prostate (-0.78; 0.4, [p-value<0.001]).
272	
273	We next explored the association between biochemical recurrence and tumor expression levels of
274	PRUNE2, PCA3 and the ratio of PRUNE2 to PCA3 expression by using several approaches.
275	First, we compared the gene expression values and their ratio by recurrence status. In patients
276	who recurred compared to those who did not, we found no significant difference in mean
277	expression values of <i>PRUNE2</i> (-1.6 vs1.58; p-value=0.68), <i>PCA3</i> (2.98 vs. 2.43; p-
278	value=0.16), or their ratio (-1.61 vs1.21, p-value=0.48). The different expression levels by
279	recurrence were not significant (Figure 1B, Supplemental Figure S1). Next, for PRUNE2
280	expression, PCA3 expression, and their ratio, we regrouped the cancer cases according to
281	whether the values were greater than (deemed "high") or less than/equal to (deemed "low") their
282	respective mean values. By using the Kaplan-Meier product limit methodology and the log-rank
283	test, we found no significant associations between high or low levels and time to recurrence for
284	PRUNE2 expression (p-value=0.24), PCA3 expression (p-value=0.22), (Figure 2 and Tables 2-
285	3), or their ratio (p-value=0.84). As a further assessment of association between gene expression
286	and time to biochemical recurrence, we used Cox proportional hazards modeling and found no
287	significant associations of time to biochemical recurrence with expression of PRUNE2 (hazard
288	ratio [HR]: 0.97; 95% confidence interval [CI]: 0.58–1.63, [p-value=0.91]) or PCA3 (HR: 1.21;
289	95% CI: 0.91–1.6, [p-value=0.19]), or their ratio (HR: 0.99; 95% CI: 0.92–1.1, [p-value=0.82]).

290 By multivariable Cox modeling, we did not find that expression of *PRUNE2*, *PCA3* or their ratio

- added any additional predictive information for recurrence to that provided by clinical or
- 292 pathological variables, as presented in supplemental results and Supplemental Table S1.
- 293

294 Validation/Confirmation Multi-Institutional Cohort

- For the analysis of a second multi-institutional validation/confirmation and expansion prostate
- 296 cancer cohort from The Cancer Genome Atlas (TCGA), patient clinical data (**Table 4**) and gene
- 297 expression data were available on men with prostate cancer (n=497). Gene expression data from
- 298 nonneoplastic prostatic tissue (hereafter termed "normal prostate") were also available in 52
- (10.5%) of the cases. The basis for the cohort has been described previously¹³. Briefly, the cohort

300 comprised men whose ages ranged from 41 to 78 years old, and who had a radical prostatectomy

- 301 for primary prostate cancer. The distribution of prostate cancer grades was as follows: Gleason
- 302 Score 3+3=6 (Group 1), 9.0%; Gleason Scores 3+4=7 or 4+3=7 (Groups 2 and 3), 49.7%;
- 303 Gleason Score 4+4=8 (Group 4), 12.9%; and Gleason Scores 4+5=9 or 5+4=9, 27.6%; and
- 304 5+5=10 (Group 5), 0.8%. For pathologic stage, most tumors were pT2c (33%), pT3a (32%), or
- 305 pT3b (27%), with a small fraction being pT4 (2%). Data on disease recurrence were available for
- 306 429 men (86.3%), with 58 (11.7% [13.5% of those with follow-up information available]) having
- 307 biochemical recurrence.
- 308
- 309 We compared gene expression levels (log₂ RNA-Seq by Expectation-Maximization
- 310 [RSEM]) in prostatic adenocarcinoma to those in normal prostate samples in the data set from
- 311 TCGA (Figure 3A): PCA3 had significantly increased expression in carcinoma [median: 12.4;
- 312 interquartile range (IQR): 10.3-13.7] as compared with normal prostate [median: 6.9; IQR: 5.2-

313	9.6, [p-value<0.001]), and PRUNE2 showed simultaneous lower expression in carcinoma
314	(median: 11.4; IQR: 10.7-12.0) versus normal prostate (median: 12.2; IQR: 11.8-12.6, [p-
315	value<0.001]). As depicted in Figure 3B, comparing tumor gene expression across different
316	prostate cancer pathologic grades, PCA3 expression was significantly lower in tumors with
317	Gleason Score greater than 7 (median: 11.6; IQR: 8.4-13.4) than in tumors with Gleason Score 7
318	(median: 12.8; IQR: 11.3-13.8, [p-value<.001]) or less than 7 (median: 12.5; IQR: 11.8-13.7, [p-
319	value=0.01]). PRUNE2 showed a small decrease in expression in tumors with Gleason Score
320	greater than 7 (median: 11.3; IQR: 10.4-11.9) as compared with tumors with Gleason Score 7
321	(median: 11.5; IQR: 10.8-12.1, [p-value=0.014]) or less than 7 (median: 11.6; IQR: 11.0-12.1,
322	[p-value=.049]). As shown in Figure 3C, comparing tumor gene expression across different
323	tumor pathologic stages, PCA3 expression was higher in pT2 tumors (median: 12.6; IQR: 11.2-
324	13.8) than in tumors that were pT3 (median: 12.2; IQR: 9.7-13.6, [p-value=0.01]) or pT4
325	(median: 12.1; IQR: 9.6-12.7, [p-value=0.61]). There was no significant difference (p-
326	value>0.05) between PRUNE2 expression levels between the different tumor stages: pT2
327	(median: 11.4; IQR: 10.7-12.1), pT3 (median: 11.3; IQR: 10.6-12.0), and pT4 (median: 11.7;
328	IQR: 10.8-12.1). We also found that the ratio of PCA3/PRUNE2 expression showed similar
329	associations with Gleason Score and pathologic stage as were seen with PCA3 expression (data
330	not shown). Overall, despite the differences in gene expression among tumor grades and stages,
331	the median expression of PCA3 was significantly higher in all tumor grades and stages than the
332	expression of PCA3 in normal prostate, and, inversely, the median expression of PRUNE2 in all
333	tumor grades and stages was significantly less than the expression of PRUNE2 in normal
334	prostate.
225	

336	As shown for the c	liscovery cohort	, we also evaluated	l the relationship	between PCA3 and

- 337 PRUNE2 expression levels and recurrence status. We found that patients who had biochemical
- 338 recurrence after prostatectomy had significantly lower tumor expression levels of PCA3 (median,
- 339 11.58; IQR, 8.28-13.14) than those who did not recur [12.51; 10.64-13.71, (p-value<0.01);
- 340 Figure 3D]. However, we did not see an association between tumor *PCA3* expression and
- 341 biochemical recurrence on multivariable Cox proportional hazards modeling when adjusting for
- 342 tumor grade, stage, and age at diagnosis [HR, 0.96; 95% CI, 0.87-1.04, (p-value=0.36)], as
- 343 presented in supplemental results and Supplemental Table S2. We did not see a significant
- 344 association between *PRUNE2* expression in those patients that had biochemical recurrence as
- 345 compared with those patients who did not recur (Supplemental Figure S2).

346

348 Discussion

349	Here we assessed the tumor and control adjacent normal prostatic glandular tissue expression of
350	the lncRNA PCA3 and the protein-coding PRUNE2 gene in two independent retrospective
351	cohorts of patients with primary organ-confined prostate cancer after treatment by radical
352	prostatectomies (Figure 4). As compared with normal prostate, we found that prostate cancer
353	showed consistent increased expression of PCA3 and consistent decreased expression of
354	PRUNE2 in tumors across a broad range of pathological attributes (i.e., Gleason grades, scores,
355	groups and stages) in both patient cohorts. These findings support the mechanistic role of a
356	tumor-specific molecular axis in which PCA3 acts as dominant-negative oncogene and PRUNE2
357	as a tumor suppressor gene in human prostate cancer and indicate that the interplay between
358	these genes is dysregulated early in prostate cancer.
359	

360 Specifically, when we compared *PCA3* expression in the validation cohort from TCGA, although 361 average expression in all grades, stages, and groups was higher than in normal prostate, we found 362 that among tumors there was significantly decreased PCA3 expression in tumors with higher 363 grades (Gleason score >7) and in higher stages (>pT2), as compared with lower grades, stages, or groups, respectively. These paradoxical findings are consistent with several early studies^{17,18} 364 365 and in particular with a recent tissue-based study of PCA3 expression in prostate cancer¹⁹. In that 366 large cohort study, lower levels of tumor *PCA3* in both biopsy and radical prostatectomy 367 specimens were associated with high-grade tumors, and in radical prostatectomy specimens 368 decreased PCA3 expression was associated with features of higher stages. Based on these results, 369 it has been proposed that PCA3 might actually represent a differentiation marker in human prostate cancer¹⁹. The finding of decreasing PCA3 expression with increasing tumor grades and 370

stages in both our study and others is broadly consistent with another previous study²⁰, which 371 372 found that the class of antisense intronic RNAs was markedly over-represented among the top 373 transcripts associated with tumor differentiation in human prostate cancer. The finding of an 374 inverse association between PCA3 expression and increasing grades and stages may also relate to 375 links between PCA3 expression and androgen receptor (AR) signaling and the likelihood of 376 *PCA3* having an important role in the early steps of prostate cancer carcinogenesis, with a 377 reduced role when the disease is more advanced. Indeed, previous work by our own group and by others indicates that *PCA3* is upregulated by AR signaling⁶⁻⁸, and that *PCA3* is also involved 378 in modulating AR signaling^{7,21}. Interestingly, it also has been shown *in vitro* that *PCA3* silencing 379 sensitizes prostate cancer cells to enzalutamide-induced decreased cell growth²². Alshalalfa et al. 380 381 suggest that because low pretreatment serum testosterone levels are associated with diseases with 382 higher grades and stages, and because of the relationship between AR signaling and PCA3 383 expression, therefore lower PCA3 expression may reflect the lower serum testosterone in these patients¹⁹. Although, we do not have any data on the pretreatment serum concentration of 384 385 testosterone and other androgens, our tumor PCA3 expression findings could perhaps be 386 consistent with that interpretation.

387

Because prostate cancers, especially Gleason Score 7 (Groups 2 and 3) tumors, are quite frequent (about half of the total cases) and show divergent clinical behavior, there is great interest in developing prognostic biomarkers for risk stratification. Studies on the association of *PCA3* expression levels with outcome and prognosis show conflicting results²³, and unlike this present study, most prior reports are based on urinary *PCA3* expression²⁴⁻²⁶. Our exploration of the validation cohort from TCGA, which comprised a wide spectrum of tumor grades and stages,

394 revealed an association between lower levels of tumor PCA3 expression and biochemical 395 recurrence; however, this association was not found after taking grade and stage into account. 396 This finding makes sense, as increasing grade and stage are both variables that are associated with lower PCA3 expression. In their tissue-based cohort, Alshalalfa et al.¹⁹ also found an 397 398 association between low PCA3 levels and adverse outcomes, including biochemical recurrence, 399 metastasis and prostate cancer-specific mortality; however, it is not clear whether such findings 400 are independent of clinical and pathological variables (such as Gleason grade, stage, and group), 401 as a multivariable analysis was not reported. For the discovery cohort of patients, we selected 402 organ-confined, intermediate-risk tumors (Gleason groups 2 and 3, with tumor stages pT2 and 403 pT3) where prognostic information might be expected to be most helpful clinically, to test for an 404 association with outcome. We did not see any association between tumor PCA3 expression and 405 biochemical recurrence.

406

407 *PRUNE2*, a human homolog of the *Drosophila prune* gene, encodes for a protein with BCH, DHHA2, and PPX1 functional domains⁷. The BCH domain can inhibit the Rho family of 408 409 proteins, small GTPases with roles in cell transformation, migration and metastasis, and cell 410 cycle progression^{5,27}. Evidence is accumulating that *PRUNE2* might act as a tumor suppressor 411 gene. Loss-of-function mutations have been described in several tumor types, including germline and somatic mutations in parathyroid cancer²⁸ and somatic mutations in solid papillary 412 carcinoma²⁹, while high expression of PRUNE2 protein correlates with favorable prognosis in 413 414 neuroblastoma³⁰. Others have shown evidence of inactivating *PRUNE2* mutations in Merkel cell carcinoma³¹ and that the restoration of downregulated PRUNE2 in oral cancer suppresses tumor 415 cell migration³², further supporting the role of *PRUNE2* as a tumor suppressor. In prostate 416

cancer, the evidence is limited and controversial: an early report found that PRUNE2 expression 417 418 was upregulated in prostate cancer and metastases in a small number of samples, and was androgen-inducible in prostate cancer cells⁵. However, a subsequent study on a larger number of 419 420 samples found that *PRUNE2* expression either decreased or did not increase in aggressive 421 prostate cancer, and that *PRUNE2* expression was not androgen-inducible¹⁷. 422 Altogether, the findings in the current study provide additional support for our previous findings⁸ 423 424 that *PRUNE2* acts as a functional tumor suppressor gene in human prostate cancer. Here we 425 described consistently lower expression of *PRUNE2* in prostate cancers of all grades and stages 426 as compared to normal prostate. The findings in our present study are also consistent with the

427 negative regulation of *PRUNE2* by *PCA3* in prostate cancer. We found no significant differences

428 in *PRUNE2* expression across tumor stage, and only a small decrease in expression with

429 increasing tumor grade, suggesting that loss of *PRUNE2* tumor suppressor activity is an early

430 molecular event in prostate cancer. We are not aware of any prior reports of the prognostic

431 significance of tumor *PRUNE2* expression in prostate cancer but, at least in this retrospective

432 study of two independent prostate cancer patient cohorts, we did not find any association

433 between *PRUNE2* expression and biochemical outcomes.

434

Strengths of this study include that broadly consistent findings were described in the two
independent well-characterized clinically annotated primary prostate cancer cohorts used for
analysis, and that the findings were robust across multiple assays in the discovery patient cohort
and between the different methods of measurement of gene expression used in the two cohorts.
The assessment of *PCA3* expression directly and specifically in tissue (as opposed to urine) is a

440 novelty and a strength as our primary goal was the study of the *PRUNE2/PCA3* regulatory axis 441 in human prostate cancer. We reasoned that the study of tissue expression is likely more 442 informative of tumor biology than traditional urinalysis, not least of all because urinary 443 expression, though very well characterized, could by subject to potential confounding issues such 444 as RNA stability in urine or the contribution of differential urinary shedding. However, from the 445 standpoint of assessment of prognostic information, a drawback of analyzing tissue PCA3 446 expression is that the results are not directly comparable to the multiple previous studies that 447 measured urinary PCA3 scores and ultimately led to FDA and EMA approval for clinical 448 applications in the US and EU. Moreover, while we did find consistent findings with a large 449 tissue cohort study relating *PCA3* expression and biochemical recurrence¹⁹, the analysis 450 presented here was limited in its ability to unequivocally determine the prognostic value of PCA3 451 and *PRUNE2* expression as the overall proportion of patients with biochemical recurrences was 452 relatively low. Finally, we were not able to fully address the relationship of reciprocal gene 453 expression of *PCA3* and *PRUNE2* to the outcomes of metastases and prostate cancer-specific 454 deaths, again due to the relative paucity of these events.

455

In conclusion, we found consistent upregulation of *PCA3* and downregulation of *PRUNE2* in prostate cancer as compared with normal prostate in two retrospective and independent patient cohorts (summarized in **Figure 4**), supporting that *PCA3* and *PRUNE3* function as an oncogene and a tumor suppressor gene, respectively, in human prostate cancer. The inverse correlation of *PCA3* and *PRUNE2* expression is consistent with our prior findings of a functional interplay between the two genes as part of a unique regulatory unit functioning at a single genetic locus in prostate cancer cells with *PCA3* negatively down-regulating *PRUNE2* expression⁸. The

463 mechanistic dysregulation of *PCA3* and *PRUNE2* is observed across the spectrum of tumor

- 464 grades and stages, suggesting that this is an early and stable molecular event in prostate cancer.
- 465 On the other hand, we have not detected any regulatory effects of *PRUNE2/PCA3* in late genetic
- 466 events such as prostate cancer progressing to biochemical recurrence, which includes the
- 467 development of local tumor recurrence and/or the development of metastatic disease. The
- 468 findings presented here represent additional evidence for the functional reciprocal co-regulation
- 469 of *PCA3* and *PRUNE2* in the setting of early tumorigenesis but not in late events in human
- 470 prostate cancer. Taken together along with the well-documented specificity of *PCA3*
- 471 overexpression, our findings establish the *PCA3/PRUNE2* regulatory axis as an attractive early
- 472 molecular target candidate for intervention in the therapy of human prostate cancer.

473

475

476 Author contributions

- 477 RCL, MB, EDN, DJM, RP, WA conceptualized the project; RCL, MB, TLS, AMT, JW, RD,
- 478 JHL, AR, ASD, MAA, DNN, ITS, EDN, DJM collected and curated the data; RCL, MB, TLS,
- 479 AMT, JW, RD, JHL, AR, ASD, MAA, DNN, ITS, EDN, DJM performed experiments and
- 480 provided reagents or critical insights; RCL, MB, TLS, AMT, JW, RD, JHL, AR, ASD, MAA,
- 481 DNN, ITS, EDN, IC, DJM, WKC, RP, WA analyzed the data; RCL, MB, EDN, DJM, RP, WA
- 482 wrote the first manuscript draft to which all authors contributed edits; RCL, EDN, DJM, RP, WA
- 483 obtained funding for the study. RCL, MB, RP, WA, supervised the study.

484

485 Acknowledgements

486 We received support from the Human Tissue Repository and Tissue Analysis Shared Resource

487 from the Department of Pathology of the University of New Mexico School of Medicine and a

488 pilot award from the University of New Mexico Comprehensive Cancer Center. RP and WA

489 were supported by awards from the Levy-Longenbaugh Donor-Advised Fund and the Prostate

490 Cancer Foundation. EDN reports research fellowship support from the Brazilian National

491 Council for Scientific and Technological Development (CNPq), Brazil, and the Associação

492 Beneficente Alzira Denise Hertzog Silva (ABADHS), Brazil. This work has been funded in part

493 by the NCI Cancer Center Support Grants (CCSG; P30) to the University of New Mexico

494 Comprehensive Cancer Center (CA118100) and the Rutgers Cancer Institute of New Jersey

495 (CA072720). The results shown here are in part based upon data generated by the TCGA

496 Research Network: https://www.cancer.gov/tcga. These data have been presented in part at the

497 2017 American Society of Clinical Oncology Annual Meeting:

498

499 Richard C. Lauer, Marc Barry, Jin Wu, Ji-Hyun Lee, Dennis J. McCance, Ruofei Du, Ar	499	Richard C. Lauer.	, Marc Barry,	Jin Wu, Ji-H	yun Lee, Dennis J	. McCance.	Ruofei Du,	Arpi
---	-----	-------------------	---------------	--------------	-------------------	------------	------------	------

- 500 Rao, Andrey S. Dobroff, Emmanuel Dias-Neto, Isan Chen, Renata Pasqualini, and Wadih Arap.
- 501 Evaluation of *PRUNE2* and *PCA3* expression as metastasis predictors in Gleason 7 prostate
- 502 cancer. J Clin Oncol 2017; 35:15 suppl, e16583.

503

- 504 Richard C. Lauer, Marc Barry, Jin Wu, Ji-Hyun Lee, Dennis J. McCance, Ruofei Du, Arpit
- 505 Rao, Andrey S. Dobroff, Emmanuel Dias-Neto, Isan Chen, Renata Pasqualini, and Wadih Arap.
- 506 PRUNE2 and PCA3 expression in paired non-malignant and tumor specimens from radical
- 507 prostatectomy patients with Gleason score 7 prostate cancer. *J Clin Oncol* 2017;

508 35:15 suppl, e16582.

509

- 510 Emmanuel Dias-Neto, Diana N. Nunes, Andrew M. Thomas, Tracey L. Smith, Arpit Rao,
- 511 Richard C. Lauer, Isan Chen, Wadih Arap, Renata Pasqualini. PCA3 upregulation in prostate
- 512 cancer: Analysis in a cohort of 497 subjects from TCGA. *J Clin Oncol* 2017 35:15_suppl,

513 e16578.

514

515 Competing interest: The University of New Mexico filed patent applications on PRUNE2-516 related technology (inventors: DNN, EDN, RP, and WA). Those applications were briefly 517 optioned by MBrace Therapeutics, but the applications have since been abandoned and the 518 agreements terminated. WA and RP are founders and equity stockholders of PhageNova Bio, 519 Inc. and of MBrace Therapeutics, Inc.; RP also serves as the Chief Scientific Officer and a paid 520 consultant of PhageNova Bio and as a member of the Board of Directors and a paid consultant

- 521 for MBrace Therapeutics. IC serves as the Chief Executive Officer of MBrace Therapeutics.
- 522 Mbrace did not provide financial support for the present work. WKC is a founder and
- 523 shareholder of Interleukin Combinatorial Therapies, Inc., InVaMet, Inc., and io9, LLC; none of
- 524 these companies provided funds or participated in the present work. These arrangements are
- 525 managed in accordance with the established institutional conflict of interest policies for the
- 526 respective institutions. The remaining authors have declared no potential competing interests
- 527 exist.
- 528
- 529

530 **References:**

- 531 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin.
- 532 Jan 2021;71(1):7-33. doi:10.3322/caac.21654
- 533 2. Arun G, Diermeier SD, Spector DL. Therapeutic Targeting of Long Non-Coding RNAs
- 534 in Cancer. Trends Mol Med. Mar 2018;24(3):257-277. doi:10.1016/j.molmed.2018.01.001
- 535 3. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific
- 536 gene, highly overexpressed in prostate cancer. Cancer Res. Dec 1 1999;59(23):5975-9.
- 4. de Kok JB, Verhaegh GW, Roelofs RW, et al. DD3(PCA3), a very sensitive and specific
- marker to detect prostate tumors. *Cancer Res.* May 1 2002;62(9):2695-8.
- 539 5. Clarke RA, Zhao Z, Guo AY, et al. New genomic structure for prostate cancer specific
- 540 gene PCA3 within BMCC1: implications for prostate cancer detection and progression. *PLoS*
- 541 One. 2009;4(3):e4995. doi:10.1371/journal.pone.0004995
- 542 6. Teixeira AA, Marchio S, Dias-Neto E, et al. Going viral? Linking the etiology of human
- 543 prostate cancer to the PCA3 long noncoding RNA and oncogenic viruses. *EMBO Mol Med.* Oct
- 544 2017;9(10):1327-1330. doi:10.15252/emmm.201708072
- 545 7. Ferreira LB, Palumbo A, de Mello KD, et al. PCA3 noncoding RNA is involved in the
- 546 control of prostate-cancer cell survival and modulates androgen receptor signaling. *BMC Cancer*.
- 547 Nov 6 2012;12:507. doi:10.1186/1471-2407-12-507
- 548 8. Salameh A, Lee AK, Cardo-Vila M, et al. PRUNE2 is a human prostate cancer
- suppressor regulated by the intronic long noncoding RNA PCA3. Proc Natl Acad Sci USA. Jul
- 550 7 2015;112(27):8403-8. doi:10.1073/pnas.1507882112
- 551 9. Gordetsky J, Epstein J. Grading of prostatic adenocarcinoma: current state and prognostic
- 552 implications. *Diagn Pathol*. Mar 9 2016;11:25. doi:10.1186/s13000-016-0478-2

553	10.	van Leenders G.	, van der Kwast TH	. Grignon DJ. et	t al. The	2019 International Socie	tv of

554 Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am J

555 Surg Pathol. Aug 2020;44(8):e87-e99. doi:10.1097/PAS.00000000001497

- 556 11. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time
- quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods*. Dec 2001;25(4):402-8.
- 558 doi:10.1006/meth.2001.1262
- 559 12. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time
- 560 quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome*
- 561 Biol. Jun 18 2002;3(7):RESEARCH0034. doi:10.1186/gb-2002-3-7-research0034
- 562 13. Cancer Genome Atlas Research N. The Molecular Taxonomy of Primary Prostate
- 563 Cancer. Cell. Nov 5 2015;163(4):1011-25. doi:10.1016/j.cell.2015.10.025
- 564 14. University of North Carolina TCGA Genome Characterization Center. TCGA prostate
- adenocarcinoma (PRAD) gene expression by RNAseq (polyA+ IlluminaHiSeq). 2017.
- 566 https://xenabrowser.net/datapages/?dataset=TCGA.PRAD.sampleMap%2FHiSeqV2&host=https
- 567 %3A%2F%2Ftcga.xenahubs.net&removeHub=https%3A%2F%2Fxena.treehouse.gi.ucsc.edu%3
- 568 A443
- 569 15. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or
- 570 without a reference genome. BMC Bioinformatics. Aug 4 2011;12:323. doi:10.1186/1471-2105-
- 571 12-323
- 572 16. Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data
 573 via the Xena platform. *Nat Biotechnol.* 06 2020;38(6):675-678. doi:10.1038/s41587-020-0546-8


- 574 17. Salagierski M, Verhaegh GW, Jannink SA, Smit FP, Hessels D, Schalken JA. Differential
- 575 expression of PCA3 and its overlapping PRUNE2 transcript in prostate cancer. *Prostate*. Jan 1
- 576 2010;70(1):70-8. doi:10.1002/pros.21040
- 577 18. Balcerczak E, Mirowski M, Sasor A, Wierzbicki R. Expression of p65, DD3 and c-erbB2
- 578 genes in prostate cancer. *Neoplasma*. 2003;50(2):97-101.
- 579 19. Alshalalfa M, Verhaegh GW, Gibb EA, et al. Low PCA3 expression is a marker of poor
- 580 differentiation in localized prostate tumors: exploratory analysis from 12,076 patients.
- 581 Oncotarget. Aug 1 2017;8(31):50804-50813. doi:10.18632/oncotarget.15133
- 582 20. Reis EM, Nakaya HI, Louro R, et al. Antisense intronic non-coding RNA levels correlate
- to the degree of tumor differentiation in prostate cancer. Oncogene. Aug 26 2004;23(39):6684-
- 584 92. doi:10.1038/sj.onc.1207880
- 585 21. Lemos AE, Ferreira LB, Batoreu NM, de Freitas PP, Bonamino MH, Gimba ER. PCA3
- 586 long noncoding RNA modulates the expression of key cancer-related genes in LNCaP prostate
- 587 cancer cells. *Tumour Biol*. Aug 2016;37(8):11339-48. doi:10.1007/s13277-016-5012-3
- 588 22. Ozgur E, Celik AI, Darendeliler E, Gezer U. PCA3 Silencing Sensitizes Prostate Cancer
- 589 Cells to Enzalutamide-mediated Androgen Receptor Blockade. Anticancer Res. Jul
- 590 2017;37(7):3631-3637. doi:10.21873/anticanres.11733
- 591 23. Loeb S, Partin AW. Review of the literature: PCA3 for prostate cancer risk assessment
- 592 and prognostication. *Rev Urol.* 2011;13(4):e191-5.
- 593 24. Loeb S, Bruinsma SM, Nicholson J, et al. Active surveillance for prostate cancer: a
- 594 systematic review of clinicopathologic variables and biomarkers for risk stratification. *Eur Urol.*
- 595 Apr 2015;67(4):619-26. doi:10.1016/j.eururo.2014.10.010

- 596 25. Lemos AEG, Matos ADR, Ferreira LB, Gimba ERP. The long non-coding RNA PCA3:
- an update of its functions and clinical applications as a biomarker in prostate cancer. *Oncotarget*.
- 598 Nov 12 2019;10(61):6589-6603. doi:10.18632/oncotarget.27284
- 599 26. Fenstermaker M, Mendhiratta N, Bjurlin MA, et al. Risk Stratification by Urinary
- 600 Prostate Cancer Gene 3 Testing Before Magnetic Resonance Imaging-Ultrasound Fusion-
- 601 targeted Prostate Biopsy Among Men With No History of Biopsy. Urology. Jan 2017;99:174-
- 602 179. doi:10.1016/j.urology.2016.08.022
- 603 27. Iwama E, Tsuchimoto D, Iyama T, et al. Cancer-related PRUNE2 protein is associated
- 604 with nucleotides and is highly expressed in mature nerve tissues. J Mol Neurosci. Jun
- 605 2011;44(2):103-14. doi:10.1007/s12031-010-9490-2
- 606 28. Yu W, McPherson JR, Stevenson M, et al. Whole-exome sequencing studies of
- 607 parathyroid carcinomas reveal novel PRUNE2 mutations, distinctive mutational spectra related
- 608 to APOBEC-catalyzed DNA mutagenesis and mutational enrichment in kinases associated with
- 609 cell migration and invasion. J Clin Endocrinol Metab. Feb 2015;100(2):E360-4.
- 610 doi:10.1210/jc.2014-3238
- 611 29. Alsadoun N, MacGrogan G, Truntzer C, et al. Solid papillary carcinoma with reverse
- 612 polarity of the breast harbors specific morphologic, immunohistochemical and molecular profile
- 613 in comparison with other benign or malignant papillary lesions of the breast: a comparative study
- 614 of 9 additional cases. *Mod Pathol*. Sep 2018;31(9):1367-1380. doi:10.1038/s41379-018-0047-1
- 615 30. Machida T, Fujita T, Ooo ML, et al. Increased expression of proapoptotic BMCC1, a
- 616 novel gene with the BNIP2 and Cdc42GAP homology (BCH) domain, is associated with
- favorable prognosis in human neuroblastomas. *Oncogene*. Mar 23 2006;25(13):1931-42.
- 618 doi:10.1038/sj.onc.1209225

- 619 31. Harms PW, Vats P, Verhaegen ME, et al. The Distinctive Mutational Spectra of
- 620 Polyomavirus-Negative Merkel Cell Carcinoma. *Cancer Res.* Sep 15 2015;75(18):3720-3727.
- 621 doi:10.1158/0008-5472.CAN-15-0702
- 622 32. Su SC, Yeh CM, Lin CW, et al. A novel melatonin-regulated lncRNA suppresses TPA-
- 623 induced oral cancer cell motility through replenishing PRUNE2 expression. J Pineal Res. Oct
- 624 2021;71(3):e12760. doi:10.1111/jpi.12760


625

627 Figures:





630 Figure 1: Analyses of discovery prostate cancer cohort. (A) PRUNE2 and PCA3 expression in 631 tumor (Fig. 1 - Source Data File 1) and nonneoplastic (Fig. 1 - Source Data File 2) prostatic 632 samples. Calculated values available in Fig. 1 - Source Data File 3. (B) Tumor PCA3 expression 633 by biochemical recurrence status. PCA3 expression in patients without versus with biochemical 634 recurrence in the discovery cohort. No significant difference in median expression was seen in 635 this cohort. Box plots of gene expression (normalized expression) in the discovery cohort. The 636 horizontal line within each box represents the median value, while the box represents the 637 interquartile range, and the whiskers extend out to 1.5 times the interquartile range. Outliers are 638 represented by circles. P-values are noted for the indicated comparisons.



641 **Figure 2**. Kaplan-Meier curves illustrating time to event (biochemical recurrence) among


642 patients post-prostatectomy from the discovery cohort, stratified by "high" gene expression

643 (greater than mean expression, red line) versus "low" gene expression (less than or equal to mean 644 expression, blue line), for (A) tumor *PRUNE2* expression, and (B) tumor *PCA3* expression.


CAF = There is service size if is an expression, and (**B**) further services to the service size is the service of the service size is the service size of the service size is the service size of the servi


645 There is was no significant association of high versus low expression levels and time to

646 recurrence by log rank testing for either *PRUNE2* or *PCA3*.










661



relationship in paired prostate cancer and adjacent normal prostate was analyzed in two

664 independent retrospective cohorts of clinically-annotated cases post-radical prostatectomy: a

- 665 single-institution discovery cohort (n=107) and a multi-institution validation cohort (n=497). We
- also serially examined clinical/pathological variables including time to disease recurrence.
- 667 Created with BioRender.com

669 Tables:

670 **Table 1.** Discovery Cohort: clinicopathologic features of the 107 patients in this study who had

671 radical prostatectomy at UNM for localized prostatic adenocarcinoma (Further details in **Table 1**

672 – Source Data File 1 and Table 1 – Supplemental Figure 1)

Variable	<u>Number</u>	% or Mean (STD; Range)				
Age (years)	107	62.8 (8.4; 45-84)				
Race						
Non-Hispanic White	91	85				
Hispanic	8	7.5				
American Indian	3	2.8				
African American	3	2.8				
Other	2	1.9				
Post-prostatectomy Gleason Grade (Grade Group)						
3 + 4 = 7 (Grade Group 2)	93	86.9				
4 + 3 = 7 (Grade Group 3)	14	13.1				
Pathologic Stage						
pT2	80	74.8				
pT3a	27	25.2				
Biochemical Recurrence Status						
No	83	77.6				
Yes	19	17.8				
LTF	5	4.7				

673 Abbreviations: STD, standard deviation; LTF, lost to follow up

675

676 677

Table 2. Number of patients at risk over time (see Figure 2A)

678

	Years Post Radical Prostatectomy			679	
PRUNE2 Expression	0	5	10	15	(00
High	51	15	5	0	680
Low	56	14	2	0	601
					001

682 **Table 3**. Number of patients at risk over time (see Figure 2B)

				(04
PCA3 Expression	0	5	10	15 084
High	59	16	2	0
Low	48	13	5	0

⁶⁷⁴

Table 4. Validation cohort: clinicopathologic features of the 497 patients in the prostate cancer

686	TCGA data set, with a total of 549 tissue samples included.					
	Variable	Number	% or Mean (STD; Range)			
	Age (years)	497	61 (6.8; 41-78)			

Vital Status		
Alive	487	97.9
Dead	10	2.1
Sample Type		
Primary tumor	497	
Normal (non-malignant) prostate	52	
Post-prostatectomy Gleason Grade (G	Grade Group)	
6 (Grade Group 1)	45	9
7 (Grade Groups 2 & 3)	247	49.7
8 (Grade Group 4)	64	12.9
9 (Grade Group 5)	137	27.6
10 (Grade Group 5)	4	0.8
Pathologic Stage		
pT2a	13	2.6
pT2b	10	2
pT2c	164	33
pT3a	158	32
pT3b	135	27
pT4	10	2
Unknown	7	1.4
Biochemical Recurrence Status		
No	371	74.6
Yes	58	11.7
Unknown	68	13.7
<u>Unknown</u> Abbraviation: STD standard daviatic		13./

687 Abbreviation: STD, standard deviation

688

690 Source Data:

- 691 Table 1 Source Data File 1. Discovery Cohort. Clinicopathologic features of the 107 patients
 692 in this study who had radical prostatectomy at UNM for localized prostatic adenocarcinoma
- 693
 694 Figure 1 Source Data File 1. Analyses of discovery prostate cancer cohort. Raw values of
- 695 *PRUNE2* and *PCA3* expression in tumor prostatic samples.
- 696
- Figure 1 Source Data File 2. Analyses of discovery prostate cancer cohort. Raw values of
 PRUNE2 and *PCA3* expression in nonneoplastic prostatic samples.
- 699
- 700 Figure 1 Source Data File 3. Analyses of discovery prostate cancer cohort. Calculated
- values of *PRUNE2* and *PCA3* expression in tumor and nonneoplastic prostatic samples.
- 702
- 703 Source Code File. R code and SAS code of descriptive statistics.
- 704

705 Supplemental Material:

706 Results

707 In the discovery cohort, to further assess the association between time to biochemical recurrence 708 and the gene expression of *PRUNE2* and *PCA3* and the ratio of their expressions, and to take into 709 account possible confounding by clinicopathological variables, we performed multivariate Cox 710 proportional hazards regression modeling (raw data available in Supplemental File 1 tables and 711 code). As there may be possible correlations between tumor Gleason Grade (GG) and tumor 712 pathologic stage (PS), we created a composite categorical variable ("GG-PS") representing the 713 four possibilities in the discovery cohort: 3+4/pT2, 4+3/pT2, 3+4/pT3a, 4+3/pT3a. We then used 714 two approaches to model outcome. 715 716 In the first approach, we fit four different Cox models. The explanatory variables in these models 717 were as follows: model 1 ("GG PS model") – GG PS only; model 2 ("PRUNE2 model") – 718 *PRUNE2* expression, age, race, GG PS, and interaction between GG PS and *PRUNE2* 719 expression; model 3 ("PCA3 model") – PCA3 expression, age, race, GG PS, and interaction 720 between GG PS and PCA3 expression; and model 4 ("Ratio model") – PRUNE2/PCA3 ratio, 721 age, race, GG PS, and interaction between GG PS and the ratio. The goodness-of-fit of the 722 models were compared using the Akaike Information Criterion (AIC), and the results are 723 summarized in **Supplemental Table S1**. As a lower value of AIC indicates a better association 724 fit, the model comparison indicates that the model with GG PS only (model 1) represents the 725 best fit for the data, and does not suggest that the expression of *PRUNE2*, *PCA3* or their ratio 726 adds to the ability of pathology grade and stage to predict biochemical recurrence.

727

728	As a second multivariable approach to an assessment of the association of time to biochemical
729	recurrence and gene expression, we created a multivariable model, including the following
730	variables: expression of PRUNE2, expression of PCA3, age, race, the composite variable
731	GG_PS, interaction between PRUNE2 expression and GG_PS, and interaction between PCA3
732	expression and GG_PS. In this case, a stepwise selection algorithm was used for model selection,
733	and only the model with Gleason score and pathologic stage (GG_PS) was selected, as none of
734	the other variables had a p-value less than the specified significance level of 0.25 (data not
735	shown).
736	
737	In the TCGA cohort, we used Cox proportional hazards modeling to assess the association of
738	tumor PCA3 expression, adjusting for tumor grade, tumor stage, and age at diagnosis. The results
739	are summarized in Supplemental Table S2. Briefly, on multivariable modeling, there was an
740	association between tumor grade and stage with recurrence, we did not find that tumor PCA3
741	expression was associated with biochemical recurrence [HR, 0.96; 95% CI 0.87-1.04, (p-
742	value=0.36)].
743	
744	Methods
745	Statistical Analysis for Quantifying the expression of PCA3 and PRUNE2. There were
746	combinations of assays and control genes used for quantifying the expression of PCA3 and
747	PRUNE2 in this study. Explicitly, there were 9 duplex mixes for PRUNE2: PR1C1, PR1C2,
748	PR1C3, PR2C1, PR2C2, PR2C3, PR3C1, PR3C2, PR3C3; and 6 duplex mixes for PCA3:
749	PC1C1, PC1C2, PC1C3, PC2C1, PC2C2, PC3C3, where the first 3 letters denote an assay and

750 last two letters denote a control gene being used in a particular run. For example, PC2C2 denotes

751	the second assay for <i>PCA3</i> (Hs03462121_m1, detailed in Methods) and the second endogenous
752	control gene (Hs02800695_m1, detailed in Methods) were used for that specific experiment.
753	is to denote the logarithmic number of PCR cycle when the fluorescent signal passes a
754	threshold value. Let $\Delta = \frac{1}{3} \int_{-\infty}^{\infty} \frac{1}{$
755	gene expression (relative to a control gene), resulting in a positive value meaning an upregulated
756	gene's expression.
757	The experiment was completed 3 times for each gene duplex mix, e.g. we have three data points
758	of PC2C2 measure for a tumor sample. The median of the three $-\Delta$ values is summarized to
759	estimate the gene expression of a particular gene duplex mix. We then looked at both mean and

760 median of 9 estimates for *PRUNE2* and 6 estimates for *PCA3*, separately (data not shown). We

761 did not see any significant difference utilizing mean or median in this or subsequent analyses.

763 Supplemental Tables:


Supplemental Table S1. Discovery cohort multivariable model

Model	Akaike Information Criterion Score		
PS_GG model	157.2		
PRUNE2 model	162.9		
PCA3 model	166.2		
Ratio model	162.2		


Supplemental Table S2. Validation cohort multivariable cox model


	Hazard Ratio (HR)	95% CI	p-value	
PCA3	0.963	0.888 - 1.044	0.36	
Gleason Grade	1.558	1.147 - 2.117	< 0.01	
Pathologic Stage T3	3.596	1.360 - 9.512	< 0.01	
Pathologic Stage T4	1.860	0.206 - 16.82	0.58	
Age at Diagnosis	1.000	0.960 - 1.043	0.99	

769 Supplemental Figures:




Supplemental Figure S1: Discovery cohort - no significant difference in tumor *PRUNE2* expression by biochemical recurrence status.





781 expression by biochemical recurrence status

784



786 Table 1 - Supplemental Figure 1: Flow diagram of Discovery Cohort selection criteria and

787 clinicopathological characteristics available.